Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator
US-9359313-B2 · Jun 7, 2016 · US
Compositions comprising metformin and a glucokinase activator
US10363244B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10363244-B2 |
| Application number | US-201816058512-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 8, 2018 |
| Priority date | May 26, 2010 |
| Publication date | Jul 30, 2019 |
| Grant date | Jul 30, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides uses of a glucokinase activator in combination with metformin. Uses include treating type 2 diabetes, lowering blood glucose, improving insulin sensitivity, enhancing phosphorylation of glucose, and improving the therapeutic effectiveness of metformin. The invention also provides pharmaceutical compositions that comprise a GK activator and metformin. The invention also provides a salt formed between metformin and a GK activator.
First claim
Opening claim text (preview).
What is claimed is: 1. A pharmaceutical composition comprising: (a) {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid or a pharmaceutically acceptable salt thereof, (b) less than 1000 mg of metformin, and (c) at least one pharmaceutically acceptable carrier, excipient, diluent, or a mixture thereof.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
for hyperglycaemia, e.g. antidiabetics · CPC title
for glucose homeostasis (pancreatic hormones A61P5/48) · CPC title
Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) · CPC title
not condensed and containing further heterocyclic rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10363244B2 cover?
- The present invention provides uses of a glucokinase activator in combination with metformin. Uses include treating type 2 diabetes, lowering blood glucose, improving insulin sensitivity, enhancing phosphorylation of glucose, and improving the therapeutic effectiveness of metformin. The invention also provides pharmaceutical compositions that comprise a GK activator and metformin. The invention…
- Who is the assignee on this patent?
- Vtv Therapeutics Llc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/155. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).